secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031085
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics appoints Jonathan Finn to board of directors and audit committee
--------------------------------------------------------------------------------

- Jonathan Finn appointed to board as Class I director and audit committee member, effective November 9, 2023.
- Finn succeeds Greg Weaver and will serve until the 2025 Annual Meeting of Stockholders.
- Finn brings over 25 years of financial industry experience, focusing on early to mid-stage biotech and tech companies.
- Compensation follows standard non-employee director terms as per 2023 proxy; standard indemnification agreement to be entered.
- No arrangements, family relationships, or material interests in any transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/atos20231106_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer